IP Library › Granted Patent US 9,750,690
Granted Patent B2
US 9,750,690 · App. 14/478,818 · Granted Sep 5, 2017

Circulation of components during microfluidization and/or homogenization of emulsions

Inventors: Harald Rueckl (Alsfeld, DE); Hanno Scheffczik (Marburg, DE); Barbara Santry (Meath, IE)
Assignee: NOVARTIS AG
A61K9/1075A61K9/107A61K39/39B01F3/0807B01F5/0661B01F7/00766B01F13/1016A61K2039/55566
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,750,690
App. No.
14/478,818
Granted
Sep 5, 2017
Kind
B2
Abstract

An improved method for the manufacture of an oil-in-water emulsion involves circulation of emulsion components between a first container and a second container via a homogenizer and/or via a microfluidization device. Usefully, all of the emulsion components from the first container are emptied before being returned.

Claims (22)

1. A method for a large-scale manufacture of a uniform oil-in-water emulsion, the method comprising steps of:

providing a first emulsion;

passing the first emulsion through a device at least two times, wherein the device operates under high pressure and high velocity sufficient to reduce the average size of oil droplets in the first emulsion so as to form a second emulsion; and,

filtering the second emulsion with an asymmetric hydrophilic membrane so as to form a uniform oil-in-water emulsion, characterized in that the average oil droplet size is 220 nm or less and the number of oil droplets having a size>1.2 μm is 5×10 8 /ml or less, and wherein the uniform oil-in-water emulsion has a volume more than or equal to 50 liters.

2. The method of claim 1 , wherein the first emulsion has an average oil droplet size of 5000 nm or less, and wherein the number of oil droplets having a size>1.2 μm is 5×10 11 /ml or less.

3. The method of claim 1 , wherein the second emulsion has an average oil droplet size of 500 nm or less, and wherein the number of oil droplets having a size>1.2 μm is 5×10 10 /ml or less.

4. The method of claim 1 , wherein the device comprises an auxiliary processing module and an interaction chamber.

5. The method of claim 4 , wherein the auxiliary processing module is positioned downstream of the interaction chamber.

6. The method of claim 4 , wherein the auxiliary processing module comprises a Z-type channel.

7. The method of claim 6 , wherein the auxiliary processing module comprises a plurality of Z-type channels.

8. A method for a large-scale manufacture of a pharmaceutical composition, the method comprising steps of:

providing a first emulsion;

passing the first emulsion through a device at least two times, wherein the device operates under high pressure and high velocity sufficient to reduce the average size of oil droplets in the first emulsion so as to form a second emulsion;

filtering the second emulsion with an asymmetric hydrophilic membrane so as to form a uniform oil-in-water emulsion, characterized in that the average oil droplet size is 220 nm or less and the number of oil droplets having a size>1.2 μm is 5×10 8 /ml or less, and wherein the

uniform oil-in-water emulsion has a volume more than or equal to 50 liters;

adding to the uniform oil-in-water emulsion one or more components to form a pharmaceutical composition comprising the oil-in-water emulsion.

9. The method of claim 8 , further comprising a step of sterilizing the pharmaceutical composition.

10. The method of claim 8 , wherein the pharmaceutical composition comprises an antigen.

11. The method of claim 8 , wherein the pharmaceutical composition is a vaccine.

12. The method of claim 8 , wherein the pharmaceutical composition comprises squalene.

13. The method of claim 8 , wherein the pharmaceutical composition comprises squalene, polysorbate 80 and sorbitan trioleate.

14. The method of claim 3 , wherein the first emulsion is passed through the device at least five times.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2024
From: NOVARTIS AG
To: SEQIRUS UK LIMITED
Reel/Frame 069642/0293 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2015
From: RUECKL, HARALD; SCHEFFCZIK, HANNO; SANTRY, BARBARA
To: NOVARTIS VACCINES AND DIAGNOSTICS GMBH
Reel/Frame 036227/0976 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2015
From: NOVARTIS VACCINES AND DIAGNOSTICS GMBH
To: NOVARTIS AG
Reel/Frame 036228/0087 →
Continuity (3)
Continuation 13513564
Provisional Application 61283518 · Dec 3, 2009
Related Publication 20160128937A1 · May 12, 2016